Skip to contentpdufa.bio

EPX-100 (clemizole hydrochloride)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

EPX-100 (clemizole hydrochloride) is a Harmony Biosciences Holdings, Inc. program in dravet syndrome and Lennox-Gastaut syndrome. Its next catalyst is a Readout in Dec 2026.

HRMY catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Dravet syndrome and Lennox-Gastaut syndrome. Sponsor: Harmony Biosciences Holdings, Inc. (HRMY). We track 2 catalyst events for this program: 2 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Dec 2026HRMYReadout · Q4 2027HRMY

Questions

When is EPX-100 (clemizole hydrochloride)'s next FDA decision or readout?

The next tracked catalyst for EPX-100 (clemizole hydrochloride) is a Readout in Dec 2026.

What happened at EPX-100 (clemizole hydrochloride)'s most recent FDA decision?

No FDA decision for EPX-100 (clemizole hydrochloride) is in our archive yet.

What is EPX-100 (clemizole hydrochloride) used for?

In our records EPX-100 (clemizole hydrochloride) is under review or in development for Dravet syndrome and Lennox-Gastaut syndrome.

Who makes EPX-100 (clemizole hydrochloride)?

Harmony Biosciences Holdings, Inc. (HRMY).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.